Literature DB >> 23121095

Characteristics of HPV infection over time in European women who are HIV-1 positive.

I Heard1, H A Cubie, D Mesher, P Sasieni.   

Abstract

OBJECTIVE: The objectives of the study were to investigate high-risk human papillomavirus (HR-HPV) infection and type distribution in women infected with HIV-1, and to determine the relevance of HR-HPV positivity and persistence/loss to the development of high-grade cervical disease.
DESIGN: A total of 518 European women infected with HIV attending for routine gynaecological care consented to 6-monthly follow-up visits over 3 years, with surveillance of cytology, colposcopy and histopathology, where relevant, and longer follow-up, where possible.
SETTING: European women infected with HIV attending for routine gynaecological care. POPULATION OR SAMPLE: 518 European women infected with HIV attending for gynaecological care in 6 hospital-based European centres - Dublin, Edinburgh, London, Milan, Paris, and Warsaw.
METHODS: Cervical screening was achieved by liquid-based cytology (LBC) of brush samples in PreservCyt® medium. The HPV testing of residual samples was performed by Hybrid-Capture II, with genotyping of positives using the HPV Line Blot Assay. Histology results were accessed where available. MAIN OUTCOME MEASURES: Description of high risk human papillomavirus (HR-HPV) infection and type distribution in HIV-1 infected women.
RESULTS: The estimated prevalence at baseline of any HR-HPV type was 49.5% (46.3-52.8%): 10.2% for HPV 16 and 4.3% for HPV 18. The prevalence increased with increasing immunosuppression. Multiple infections were detected in 26.8%. HR-HPV genotypes were detected in 34.9% of cases with normal cytology, in 77.2% of cases with atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion (ASCUS/LSIL) and in 90.8% of cases with high-grade SIL (HSIL). The prevalence of HPV 16 in HSIL was 38.5%, with the three most common types thereafter having prevalence rates of 19.2% (HPV 58), 19.2% (HPV 53) and 16.6% (HPV 52). The overall persistence of any high-risk type was 55.8%. We found that 6 months persistence of HPV 16 occurred in 24 women. Seven cases of high-grade cervical disease developed, and all were associated with initial/persistent HR-HPV positivity.
CONCLUSIONS: A wide diversity of HPV types was evident, and multiple infections were common. Detection or persistence of any HR-HPV was associated with a very low incidence of subsequent high-grade disease.
© 2012 The Authors BJOG An International Journal of Obstetrics and Gynaecology © 2012 RCOG.

Entities:  

Mesh:

Year:  2012        PMID: 23121095     DOI: 10.1111/1471-0528.12015

Source DB:  PubMed          Journal:  BJOG        ISSN: 1470-0328            Impact factor:   6.531


  10 in total

1.  The Intersection of HIV, Social Vulnerability, and Reproductive Health: Analysis of Women Living with HIV in Rio de Janeiro, Brazil from 1996 to 2016.

Authors:  Christine M Zachek; Lara E Coelho; Rosa M S M Domingues; Jesse L Clark; Raquel B De Boni; Paula M Luz; Ruth K Friedman; Ângela C Vasconcelos de Andrade; Valdilea G Veloso; Jordan E Lake; Beatriz Grinsztejn
Journal:  AIDS Behav       Date:  2019-06

2.  Cervical HPV infection in Romanian women infected with HIV during early childhood.

Authors:  Luminita Ene; Cristina Voinea; Claudia Stefanescu; Diana Sima; Dan Duiculescu; Sanjay R Mehta
Journal:  Int J STD AIDS       Date:  2015-09-24       Impact factor: 1.359

3.  The Need for Cervical Cancer Control in HIV-Positive and HIV-Negative Women from Romania by Primary Prevention and by Early Detection Using Clinically Validated HPV/DNA Tests.

Authors:  Ramona Gabriela Ursu; Mircea Onofriescu; Alexandru Luca; Liviu Jany Prisecariu; Silvia Olivia Sălceanu; Dragoş Nemescu; Luminiţa Smaranda Iancu
Journal:  PLoS One       Date:  2015-07-17       Impact factor: 3.240

4.  Prevalence and distribution of cervical high-risk human papillomavirus and cytological abnormalities in women living with HIV in Denmark - the SHADE.

Authors:  Kristina Thorsteinsson; Merete Storgaard; Terese L Katzenstein; Steen Ladelund; Frederikke Falkencrone Rønsholt; Isik Somuncu Johansen; Gitte Pedersen; Lailoma Hashemi; Lars Nørregård Nielsen; Lisbeth Nilas; Niels Obel; Jesper Bonde; Anne-Mette Lebech
Journal:  BMC Cancer       Date:  2016-11-08       Impact factor: 4.430

5.  Detection and genotyping of human papillomavirus (HPV) in HIV-infected women and its relationship with HPV/HIV co-infection.

Authors:  Rodolfo Miglioli Badial; Marina Carrara Dias; Bruna Stuqui; Patrícia Pereira Dos Santos Melli; Silvana Maria Quintana; Caroline Measso do Bonfim; José Antônio Cordeiro; Tatiana Rabachini; Marilia de Freitas Calmon; Paola Jocelan Scarin Provazzi; Paula Rahal
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.889

6.  Persistence of cervical high-risk human papillomavirus in women living with HIV in Denmark - the SHADE.

Authors:  Kristina Thorsteinsson; Steen Ladelund; Merete Storgaard; Terese L Katzenstein; Isik Somuncu Johansen; Gitte Pedersen; Frederikke Falkencrone Rönsholt; Lars Nørregård Nielsen; Lisbeth Nilas; Maria Franzmann; Niels Obel; Anne-Mette Lebech; Jesper Bonde
Journal:  BMC Infect Dis       Date:  2019-08-22       Impact factor: 3.090

7.  Serum and cervicovaginal IgG immune responses against α7 and α9 HPV in non-vaccinated women at risk for cervical cancer: Implication for catch-up prophylactic HPV vaccination.

Authors:  Ralph-Sydney Mboumba Bouassa; Hélène Péré; Camélia Gubavu; Thierry Prazuck; Mohammad-Ali Jenabian; David Veyer; Jean-François Meye; Antoine Touzé; Laurent Bélec
Journal:  PLoS One       Date:  2020-05-18       Impact factor: 3.240

8.  Performance of Two-Stage Cervical Cancer Screening With Primary High-Risk Human Papillomavirus Testing in Women Living With Human Immunodeficiency Virus.

Authors:  Rebecca Luckett; Neo Mogowa; Howard J Li; Adrienne Erlinger; Michele R Hacker; Katharine Esselen; Sarah Feldman; Roger Shapiro; Chelsea Morroni; Doreen Ramogola-Masire
Journal:  Obstet Gynecol       Date:  2019-10       Impact factor: 7.661

9.  Risk of cervical HPV infection and prevalence of vaccine-type and other high-risk HPV types among sexually active teens and young women (13-26 years) enrolled in the VALHIDATE study.

Authors:  Giovanna Orlando; Michela Fasolo; Francesca Mazza; Elena Ricci; Susanna Esposito; Elena Frati; Gian Vincenzo Zuccotti; Irene Cetin; Maria Gramegna; Giuliano Rizzardini; Elisabetta Tanzi
Journal:  Hum Vaccin Immunother       Date:  2014-01-15       Impact factor: 3.452

10.  High Prevalence of Cervical High-Risk Human Papillomavirus Harboring Atypical Genotypes in Human Immunodeficiency Virus -Infected and -Uninfected First-Generation Adult Immigrant Women Originating from Sub-Saharan Africa and Living in France.

Authors:  Ralph-Sydney Mboumba Bouassa; Camelia Gubavu; David Veyer; Leman Robin; Anne Gravier; Laurent Hocqueloux; Thierry Prazuck; Hélène Péré; Laurent Bélec
Journal:  J Immigr Minor Health       Date:  2021-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.